{
  "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
  "docSlug": "c241ac9edd2443452257949ce0a73d65",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 61,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a footnote citing FDA approval precedents for similar single-arm studies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/22",
  "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
  "deckJsonHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920.json",
  "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "FDA approval precedents include: Abecma/BMS (single arm study 100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (single arm study 97 patients in efficacy results population, FDA approved 2022); Elrexfio/Pfizer (single arm study 97 patients in efficacy results population, FDA approved 2023)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ec8ebb6-ba4d-418a-a9dc-fb105035919c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.96,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "table",
      "text": "Target Indication, Trial, Status columns with rows for AL Amyloidosis and Multiple Myeloma",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "635e8ffc-002e-4b3c-ac94-309cc0efa530",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.02,
        "y": 0.09
      },
      "kind": "title",
      "text": "Expansion Into Additional Sites in the U.S. Planned for Q4 2023/Q1 2024",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f406e7bb-edb8-4893-8442-aefc15c4ad4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "NXC-201 Clinical Development Plan Through FDA BLA Submissions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4dc57f0-497d-4787-95d4-c8a57d3255b1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "85fbbd21-2a88-4f23-94b3-70000d72fc4a",
      "evidence": "Visual representation of clinical trial phases and milestones over time",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 61,
      "from": 18,
      "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 19,
      "name": "David Goliath",
      "slug": "16-david-goliath",
      "bestFor": "Startups, disruptive innovation, competitive displacement",
      "matchId": "4e0762bd-4e3f-4b14-9e84-63473b64f353",
      "evidence": "The deck compares NXC-201 to existing CAR-T therapies",
      "position": 1,
      "objective": "Position NXC-201 as a superior solution",
      "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
      "confidence": 0.7,
      "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}